Glenmark reaches $29m settlement with US states in generic drug antitrust case
MLex Summary: Glenmark Pharmaceuticals reached a $29 million settlement with a coalition of 49 attorneys general to resolve claims that it conspired to artificially inflate generic drug prices and reduce competition,...To view the full article, register now.
Already a subscriber? Click here to view full article